News & Updates

Show Multimedia Only

Breastfeeding may help prevent early puberty

12 Nov 2025

Children who were breastfed during the first 4–6 months of life are less likely to have central precocious puberty (CPP), with the protective association being partially mediated by prepubertal adiposity, according to a retrospective study.

Breastfeeding may help prevent early puberty

12 Nov 2025

CRM syndrome: A new era of integrated disease management

12 Nov 2025 by

Cardiovascular (CV), renal, and metabolic (CRM) conditions are interconnected. Worsening of one condition predicts an increased risk of progression of the others, underscoring the importance of early, multifactorial intervention. In an interview with MIMS Doctor, Professor Melanie Davies from the University of Leicester, UK, called for an integrated approach to CKM care, highlighting current evidence and international guideline updates relevant to clinical practice.

CRM syndrome: A new era of integrated disease management

12 Nov 2025

Real-world data: Semaglutide reduces MACE and all-cause mortality vs dulaglutide in T2D and ASCVD

10 Nov 2025

In patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease (ASCVD), subcutaneous (SC) semaglutide Q1W was associated with lower risks of 3-point and 5-point major adverse cardiovascular events (3P- and 5P-MACE) and all-cause mortality vs dulaglutide, according to the real-world REACH study presented at the European Association for the Study of Diabetes (EASD) 2025 Annual Meeting.

Real-world data: Semaglutide reduces MACE and all-cause mortality vs dulaglutide in T2D and ASCVD

10 Nov 2025

SGLT2i reduce atherothrombotic MACE, respiratory diseases, and burden of critical illness vs DPP4i in T2D patients in HK

09 Nov 2025

In patients with type 2 diabetes (T2D), use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) is associated with a 36 percent reduction in risk of atherothrombotic major adverse cardiovascular events (MACE) vs dipeptidyl peptidase-4 inhibitors (DPP4i), a recent real-world territory-wide study in Hong Kong has shown.

SGLT2i reduce atherothrombotic MACE, respiratory diseases, and burden of critical illness vs DPP4i in T2D patients in HK

09 Nov 2025

High plasma triglycerides protect patients with PD against cognitive impairment

08 Nov 2025

In patients with Parkinson’s disease (PD), the high risk of mild cognitive impairment (MCI) at the time of diagnosis correlates with low levels of plasma triglycerides (P-TG) and an interaction between change in BMI and P-TG prior to diagnosis, reports a study.

High plasma triglycerides protect patients with PD against cognitive impairment

08 Nov 2025

Liraglutide promotes weight loss after suboptimal response to bariatric surgery

07 Nov 2025 by

For patients who are struggling to lose weight after metabolic bariatric surgery, treatment with liraglutide boosts weight-loss outcomes and helps avoid conversion surgery, as shown in a randomized clinical trial.

Liraglutide promotes weight loss after suboptimal response to bariatric surgery

07 Nov 2025

Young-onset diabetes programme provides DNA testing and precision preventive intervention to those at risk

07 Nov 2025 by

A programme targeting 9,000 adults 18–44 years of age will identify individuals with high 10-year risk of diabetes through DNA testing and provide precision preventive intervention.

Young-onset diabetes programme provides DNA testing and precision preventive intervention to those at risk

07 Nov 2025

High BMI tied to ulnar nerve entrapment development in nondiabetic individuals

06 Nov 2025 by

A longitudinal study from Sweden shows an association between high BMI and the development of ulnar nerve entrapment (UNE) in a middle-aged cohort of individuals without diabetes from northern Europe, with over 25 years of follow-up.

High BMI tied to ulnar nerve entrapment development in nondiabetic individuals

06 Nov 2025

SGLT-2i lowers autoimmune rheumatic disease risk in T2D

04 Nov 2025 by

The use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors, compared with sulfonylureas, results in a reduced risk of autoimmune rheumatic disease among adults with type 2 diabetes (T2D), reports a recent study.

SGLT-2i lowers autoimmune rheumatic disease risk in T2D

04 Nov 2025

Semaglutide safe for dialysis patients in pooled analysis

04 Nov 2025 by

Treatment with the GLP-1 receptor agonist semaglutide appears safe for patients initiating dialysis, as demonstrated in a pooled analysis presented at EASD 2025.

Semaglutide safe for dialysis patients in pooled analysis

04 Nov 2025

News & Updates

Showing Endocrinology articles

Showing

Specialty:

Breastfeeding may help prevent early puberty

Breastfeeding may help prevent early puberty

CRM syndrome: A new era of integrated disease management

CRM syndrome: A new era of integrated disease management

Real-world data: Semaglutide reduces MACE and all-cause mortality vs dulaglutide in T2D and ASCVD

Real-world data: Semaglutide reduces MACE and all-cause mortality vs dulaglutide in T2D and ASCVD

SGLT2i reduce atherothrombotic MACE, respiratory diseases, and burden of critical illness vs DPP4i in T2D patients in HK

SGLT2i reduce atherothrombotic MACE, respiratory diseases, and burden of critical illness vs DPP4i in T2D patients in HK

High plasma triglycerides protect patients with PD against cognitive impairment

High plasma triglycerides protect patients with PD against cognitive impairment

Liraglutide promotes weight loss after suboptimal response to bariatric surgery

Liraglutide promotes weight loss after suboptimal response to bariatric surgery

Young-onset diabetes programme provides DNA testing and precision preventive intervention to those at risk

Young-onset diabetes programme provides DNA testing and precision preventive intervention to those at risk

High BMI tied to ulnar nerve entrapment development in nondiabetic individuals

High BMI tied to ulnar nerve entrapment development in nondiabetic individuals

SGLT-2i lowers autoimmune rheumatic disease risk in T2D

SGLT-2i lowers autoimmune rheumatic disease risk in T2D

Semaglutide safe for dialysis patients in pooled analysis

Semaglutide safe for dialysis patients in pooled analysis